Want to live longer? Take up the challenge of this Riga VC fund
April 27, 2021
Riga-based 35 million euro longevity-focused venture capital fund LongeVC launched an in-house acceleration programme for professionals with education and work experience in the biotech industry, aiming to create high-quality startup teams.
“The venture capital fund LongeVC has created its own accelerator. This means that from time to time LongeVC will define verticals that we see the biggest potential in.”
LongeVC venture capital fund partner Sergey Jakimov Applications will be selected on a rolling basis. Applicants should fill in a form on the LongeVC website to prove their expertise in the field.
Rustam Gilfanov of Longevity-Focused LongeVC Fund Launches Acceleration Program For Startups In Biotech
tennesseedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tennesseedaily.com Daily Mail and Mail on Sunday newspapers.
Experts to present latest research on aging and longevity at the 8th Aging Research & Drug Discovery Meeting
Scheibye-Knudsen Lab, University of Copenhagen and Deep Longevity are excited to reveal the speakers for the 8th Aging Research & Drug Discovery Meeting, the largest scientific academic, and industry conference that will transpire on August 31 - September 3, 2021, on-site at the Ceremonial Hall, University of Copenhagen, and online.
According to the United Nations, the proportion of people aged over 65 now outnumber children younger than 5. The enormous growth in the elderly population is posing a significant healthcare challenge to societies worldwide most evident from the ongoing Covid-19 pandemic.
The conventional approach to medicine is the treatment of diseases. But scientists predict (Cutler and Mattson, 2006) that even thorough elimination of cancer would lead to only a 2.3-year increase in life expectancy in the United States at birth and a 1.3-year gain at the age of 65. Total elimination of pneumonia and influenza would result in gains of 0.2 and 0.5 years in life expectancy, respectively, in general.
These numbers are very small as several age-related processes and diseases manifest together later in life; therefore, the removal of only one individual cause does not result in the intuitively assumed gains in life expectancy. Aging is the key driver of a majority of these processes and diseases.
Credit: Deep Longevity Limited
27th of January, Wednesday, Hong Kong - Deep Longevity, a fully-owned subsidiary of Regent Pacific (HKEX: 0575), specializing in the development and the application of next-generation artificial intelligence (AI) for aging and longevity research, today announced the publication of an article in
Nature Aging titled Artificial Intelligence in Longevity Medicine ..
In the article the authors describe a new field of study converging AI, basic research, and medicine referred to as Longevity Medicine. Another definition for Longevity Medicine is the preventative and restorative medicine enabled by the deep aging clocks and artificial intelligence.
The article was authored by Alex Zhavoronkov, the founder and chief longevity officer of Deep Longevity, a computer scientist with a PhD in biophysics, Evelyne Yehudit Bischof, a practicing medical doctor trained in the top European and the US medical schools actively engaged in aging research and geroonco
vimarsana © 2020. All Rights Reserved.